Citation Impact
Citing Papers
Vitamin D Deficiency and Risk of Cardiovascular Disease
2008 Standout
Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance
2003
A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas
2008
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
2010 Standout
Dengue‐virus‐infected dendritic cells trigger vascular leakage through metalloproteinase overproduction
2006
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Cancer statistics, 2022
2022 Standout
Alternative Activation Is an Innate Response to Injury That Requires CD4+ T Cells to be Sustained during Chronic Infection
2007 StandoutNobel
Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour
2015
Cancer Statistics, 2021
2021 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Altered macrophage differentiation and immune dysfunction in tumor development
2007
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Immunotherapy at Large: The road to personalized cancer vaccines
2013
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Cancer despite immunosurveillance: immunoselection and immunosubversion
2006
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Personalized cancer vaccines: Targeting the cancer mutanome
2016
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
1997 Standout
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Clonal osteogenic cell lines express myogenic and adipocytic developmental potential
1991
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Bladder cancer
2016 Standout
Strategies for designing and optimizing new generation vaccines
2001
Parathyroid Hormone Has a Prosclerotic Effect on Vascular Smooth Muscle Cells
2003
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
2017
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
2010 Standout
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
2006
The Current Status of Therapy for Adult T-cell Leukaemia-Lymphoma in Japan
2003
Paradoxical roles of the immune system during cancer development
2006 Standout
Microenvironmental regulation of metastasis
2008 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
2014
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
2008
Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development
2009
Protective and pathogenic functions of macrophage subsets
2011 Standout
Cancer-related inflammation
2008 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Calreticulin exposure dictates the immunogenicity of cancer cell death
2006 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
2016
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Derangement of immune responses by myeloid suppressor cells
2003
Dengue
2007 Standout
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
2017
Improving Prospects for Targeting RAS
2015
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
2012
Reactive Oxygen Species and 12/15-Lipoxygenase Contribute to the Antiproliferative Capacity of Alternatively Activated Myeloid Cells Elicited during Helminth Infection
2005
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer.
2001
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Upstream regulatory elements necessary for expression of the rat COL1A1 promoter in transgenic mice
1994
Schistosoma mansoni Worms Induce Anergy of T Cells via Selective Up-Regulation of Programmed Death Ligand 1 on Macrophages
2004
Alternative Activation of Macrophages: An Immunologic Functional Perspective
2008 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
2016
Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage [published erratum appears in J Cell Biol 1995 Feb;128(4):following 713]
1994 Standout
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
Whole Tumor Antigen Vaccines: Where Are We?
2015
Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting
2008
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Regulation of COL1A1 expression in type I collagen producing tissues: Identification of a 49 base pair region which is required for transgene expression in bone of transgenic mice
1995
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of V. Ellen Maher being referenced
Mice infected with develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor
2001
Human Antibody Response to the Intravenous and Intraperitoneal Administration of the F(ab')2 Fragment of the OC125 Murine Monoclonal Antibody
1992
The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma
2001
Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy
2001
Combined Antitumor Therapy with the Chemotherapeutic Drug Doxorubicin and an Anti-Transferrin Receptor Immunotoxin, In Vitro and In Vivo Studies
1992
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
2013
FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.
2016
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
2013
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer
2015
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy
2017
Immunization With Mutantp53- andK-ras–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome
2005
U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
2014
Hormonal Regulation of Collagen Synthesis in a Clonal Rat Osteosarcoma Cell Line*
1986